Abstract
Alzheimer's disease (AD) is the most prevalent type of dementia. Despite considerable advances in diagnostic accuracy, diagnostic procedures that are easily accessible are still sorely needed. Blood biomarkers are therefore in the focus of research. Platelets contain a high concentration of the amyloid precursor protein (APP), which has been mentioned as a potentially useful diagnostic marker. The aim of the present study was to analyze various cell adhesion molecules (CAMs), cytokines, growth factors, and matrix metalloproteinases (MMPs) in platelets of AD and mild cognitively impaired (MCI) patients as compared to healthy controls. Our data show a significant decrease in the levels of epidermal growth factor (EGF) and of MMP-2 in platelets of AD patients and decreased levels of MMP-2 in MCI. The APP ratio was slightly but not significantly decreased in AD patients, whereas CD40L and serotonin were unchanged. Our findings demonstrate specific changes in AD platelets. Whether these biomarkers can be established as potential early diagnostic biomarkers for AD remains to be established in longitudinal studies.
Keywords: Alzheimer, biomarker, platelets, diagnosis, EGF, MMP-2, Immunohistochemistry, Serotonin
Current Alzheimer Research
Title:Matrix Metalloproteinase-2 and Epidermal Growth Factor are Decreased in Platelets of Alzheimer Patients
Volume: 9 Issue: 8
Author(s): Tanja Hochstrasser, Daniela Ehrlich, Josef Marksteiner, Barbara Sperner-Unterweger and Christian Humpel
Affiliation:
Keywords: Alzheimer, biomarker, platelets, diagnosis, EGF, MMP-2, Immunohistochemistry, Serotonin
Abstract: Alzheimer's disease (AD) is the most prevalent type of dementia. Despite considerable advances in diagnostic accuracy, diagnostic procedures that are easily accessible are still sorely needed. Blood biomarkers are therefore in the focus of research. Platelets contain a high concentration of the amyloid precursor protein (APP), which has been mentioned as a potentially useful diagnostic marker. The aim of the present study was to analyze various cell adhesion molecules (CAMs), cytokines, growth factors, and matrix metalloproteinases (MMPs) in platelets of AD and mild cognitively impaired (MCI) patients as compared to healthy controls. Our data show a significant decrease in the levels of epidermal growth factor (EGF) and of MMP-2 in platelets of AD patients and decreased levels of MMP-2 in MCI. The APP ratio was slightly but not significantly decreased in AD patients, whereas CD40L and serotonin were unchanged. Our findings demonstrate specific changes in AD platelets. Whether these biomarkers can be established as potential early diagnostic biomarkers for AD remains to be established in longitudinal studies.
Export Options
About this article
Cite this article as:
Hochstrasser Tanja, Ehrlich Daniela, Marksteiner Josef, Sperner-Unterweger Barbara and Humpel Christian, Matrix Metalloproteinase-2 and Epidermal Growth Factor are Decreased in Platelets of Alzheimer Patients, Current Alzheimer Research 2012; 9 (8) . https://dx.doi.org/10.2174/156720512803251156
DOI https://dx.doi.org/10.2174/156720512803251156 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondria as Therapeutic Targets of Estrogen Action in the Central Nervous System
Current Drug Targets - CNS & Neurological Disorders Albumin Infusion Therapy in Stroke, Sepsis and the Critically Ill
Current Nutrition & Food Science APOE Genotypes and Brain Imaging Classes in Normal Cognition, Mild Cognitive Impairment, and Alzheimer’s Disease: A Longitudinal Study
Current Alzheimer Research Risk Factors of Alzheimers Disease Among Iranian Population
Current Alzheimer Research Delivery of Anti-Viral Nucleoside Analogues to the Central Nervous System
Current Medicinal Chemistry - Anti-Infective Agents The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review
Current Molecular Pharmacology Statins as Either Immunomodulators or Anti-Cancer Drugs: Functional Activities on Tumor Stromal Cells and Natural Killer Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Metacognition and Social Functioning in Schizophrenia: Evidence, Mechanisms of Influence and Treatment Implications
Current Psychiatry Reviews Modifiable Risk Factors Associated with Alzheimer’s Disease with Special Reference to Sleep Disturbance
CNS & Neurological Disorders - Drug Targets Risk Factors for Upper GI Damage in Low-Dose Aspirin Users and the Interaction Between <i>H. pylori</i> Infection and Low-Dose Aspirin Use
Current Pharmaceutical Design Protein Kinase C – Possible Therapeutic Target to Treat Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Serum Albumin Concentration and Cognitive Impairment
Current Alzheimer Research Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy Retinoic Acid and the Gut Microbiota in Alzheimer’s Disease: Fighting Back-to-Back?
Current Alzheimer Research Targeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical Design Alzheimer's Disease: A Systemic Review of Substantial Therapeutic Targets and the Leading Multi-functional Molecules
Current Topics in Medicinal Chemistry Towards Alzheimers Disease Vaccination
Mini-Reviews in Medicinal Chemistry Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection
Current Drug Metabolism Brain Structural Effects of Antidepressant Treatment in Major Depression
Current Neuropharmacology